---
document_datetime: 2025-12-17 23:10:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/filspari.html
document_name: filspari.html
version: success
processing_time: 0.102384
conversion_datetime: 2025-12-28 05:16:53.798676
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Filspari

[RSS](/en/individual-human-medicine.xml/232656)

##### Authorised

This medicine is authorised for use in the European Union

sparsentan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Filspari](#news-on)
- [More information on Filspari](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Filspari is a medicine used to treat adults with primary immunoglobulin A nephropathy, a disease where the kidneys gradually stop working and eventually fail, requiring patients to have dialysis (a process for removing unwanted substances or excess fluid from the blood) or a kidney transplant. Primary means that the cause of the disease is unknown. The medicine is to be used in people who have at least 1 g of protein in their urine per day or a urine protein-to-creatinine ratio of at least 0.75 g/g (another measure of protein levels in the urine). Filspari was designated an 'orphan medicine' (a medicine used in rare diseases) on 19 October 2020. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2345) . Filspari contains the active substance sparsentan.

Expand section

Collapse section

## How is Filspari used?

Filspari can only be obtained with a prescription and is available as tablets to be taken by mouth once a day.

For more information about using Filspari, see the package leaflet or contact your doctor or pharmacist.

## How does Filspari work?

The active substance in Filspari, sparsentan, blocks the receptors (targets) for two hormones called endothelin and angiotensin, which are involved in processes that lead to kidney damage. By blocking these receptors, Filspari lowers the level of protein in the urine (proteinuria, a sign of kidney damage), and helps to slow progression of the disease.

## What benefits of Filspari have been shown in studies?

Filspari has been found to be effective at reducing proteinuria in people with immunoglobulin A nephropathy in a main study. The study involved 404 adults with immunoglobulin A nephropathy and high levels of proteinuria (at least 1 g per day) despite receiving other treatment to slow disease progression. It compared the effect of Filspari on proteinuria with that of irbesartan (a medicine used as part of the standard treatment of immunoglobulin A nephropathy). After 36 weeks of treatment, the level of proteinuria had dropped by an average of 50% in people receiving Filspari compared with an average of 15% in those taking irbesartan. After 2 years, these figures were 43% for people using Filspari, compared with 4% for those using irbesartan.

The study data also indicate that Filspari slows the decline in kidney function, as seen in the change in estimated glomerular filtration rate (eGFR; a measure of how well the kidneys are working). A decrease in eGFR indicates a decline in kidney function. After 2 years of treatment, eGFR had dropped by 2.9 ml/min/1.73m2/year in people receiving Filspari, compared with 3.9 ml/min/1.73m2/year in those receiving irbesartan.

## What are the risks associated with Filspari?

For the full list of side effects and restrictions with Filspari, see the package leaflet.

The most common side effects with Filspari (which may affect up to 1 in 10 people) include hypotension (low blood pressure), hyperkalaemia (high potassium levels in the blood), dizziness and peripheral oedema (swelling of the arms and legs).

The most common serious side effect, which may affect up to 1 in 100 people, is acute (sudden-onset) kidney injury.

Filspari must not be used during pregnancy. It must also not be used together with angiotensin receptor blockers or endothelin receptor antagonists (other medicines that act on the angiotensin or endothelin receptors) or with medicines called renin inhibitors.

## Why is Filspari authorised in the EU?

At the time of approval, there were limited authorised treatments for patients with immunoglobulin A nephropathy. Filspari has been shown to effectively reduce the level of excess protein in the urine and slows the decline in kidney function in adults with this disease. Treatment with Filspari is generally well tolerated, provided that appropriate precautions are taken. The European Medicines Agency therefore decided that the benefits of Filspari are greater than its risks and it can be authorised for use in the EU.

Filspari has been given 'conditional authorisation'. This means that it has been authorised on the basis of less comprehensive data than are normally required because it fulfils an unmet medical need. The Agency considers that the benefit of having the medicine available earlier outweighs any risks associated with using it while awaiting further evidence.

The company has to provide further data on Filspari. It must submit long-term results from the main study on the safety and effectiveness of Filspari in the treatment of adults with primary immunoglobulin A nephropathy. Every year, the European Medicines Agency will review any new information that becomes available.

## What measures are being taken to ensure the safe and effective use of Filspari?

The company that markets Filspari will make a patient card available to people using the medicine, which includes information about the risks to the unborn baby if the medicine is used during pregnancy and the risks of liver damage, as well as advice on when to consult a healthcare professional.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Filspari have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Filspari are continuously monitored. Suspected side effects reported with Filspari are carefully evaluated and any necessary action taken to protect patients.

## Other information about Filspari

Filspari received a conditional marketing authorisation valid throughout the EU on 19 April 2024.

Filspari : EPAR - Medicine overview

Reference Number: EMA/88878/2024

English (EN) (122.83 KB - PDF)

**First published:** 28/05/2024

[View](/en/documents/overview/filspari-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-774)

български (BG) (146.79 KB - PDF)

**First published:**

28/05/2024

[View](/bg/documents/overview/filspari-epar-medicine-overview_bg.pdf)

español (ES) (131.46 KB - PDF)

**First published:**

28/05/2024

[View](/es/documents/overview/filspari-epar-medicine-overview_es.pdf)

čeština (CS) (144.93 KB - PDF)

**First published:**

28/05/2024

[View](/cs/documents/overview/filspari-epar-medicine-overview_cs.pdf)

dansk (DA) (121.91 KB - PDF)

**First published:**

28/05/2024

[View](/da/documents/overview/filspari-epar-medicine-overview_da.pdf)

Deutsch (DE) (135.71 KB - PDF)

**First published:**

28/05/2024

[View](/de/documents/overview/filspari-epar-medicine-overview_de.pdf)

eesti keel (ET) (119.23 KB - PDF)

**First published:**

28/05/2024

[View](/et/documents/overview/filspari-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.32 KB - PDF)

**First published:**

28/05/2024

[View](/el/documents/overview/filspari-epar-medicine-overview_el.pdf)

français (FR) (123.13 KB - PDF)

**First published:**

28/05/2024

[View](/fr/documents/overview/filspari-epar-medicine-overview_fr.pdf)

hrvatski (HR) (153.05 KB - PDF)

**First published:**

28/05/2024

[View](/hr/documents/overview/filspari-epar-medicine-overview_hr.pdf)

italiano (IT) (131.13 KB - PDF)

**First published:**

28/05/2024

[View](/it/documents/overview/filspari-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (159.16 KB - PDF)

**First published:**

28/05/2024

[View](/lv/documents/overview/filspari-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.8 KB - PDF)

**First published:**

28/05/2024

[View](/lt/documents/overview/filspari-epar-medicine-overview_lt.pdf)

magyar (HU) (144.23 KB - PDF)

**First published:**

28/05/2024

[View](/hu/documents/overview/filspari-epar-medicine-overview_hu.pdf)

Malti (MT) (155.43 KB - PDF)

**First published:**

28/05/2024

[View](/mt/documents/overview/filspari-epar-medicine-overview_mt.pdf)

Nederlands (NL) (122.68 KB - PDF)

**First published:**

28/05/2024

[View](/nl/documents/overview/filspari-epar-medicine-overview_nl.pdf)

polski (PL) (158.5 KB - PDF)

**First published:**

28/05/2024

[View](/pl/documents/overview/filspari-epar-medicine-overview_pl.pdf)

português (PT) (122.42 KB - PDF)

**First published:**

28/05/2024

[View](/pt/documents/overview/filspari-epar-medicine-overview_pt.pdf)

română (RO) (152.28 KB - PDF)

**First published:**

28/05/2024

[View](/ro/documents/overview/filspari-epar-medicine-overview_ro.pdf)

slovenčina (SK) (145.32 KB - PDF)

**First published:**

28/05/2024

[View](/sk/documents/overview/filspari-epar-medicine-overview_sk.pdf)

slovenščina (SL) (141.59 KB - PDF)

**First published:**

28/05/2024

[View](/sl/documents/overview/filspari-epar-medicine-overview_sl.pdf)

Suomi (FI) (129.13 KB - PDF)

**First published:**

28/05/2024

[View](/fi/documents/overview/filspari-epar-medicine-overview_fi.pdf)

svenska (SV) (120.31 KB - PDF)

**First published:**

28/05/2024

[View](/sv/documents/overview/filspari-epar-medicine-overview_sv.pdf)

Filspari : EPAR - Risk management plan

English (EN) (2.96 MB - PDF)

**First published:** 28/05/2024

**Last updated:** 30/04/2025

[View](/en/documents/rmp/filspari-epar-risk-management-plan_en.pdf)

## Product information

Filspari : EPAR - Product information

English (EN) (371.44 KB - PDF)

**First published:** 28/05/2024

**Last updated:** 08/12/2025

[View](/en/documents/product-information/filspari-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-531)

български (BG) (496.83 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/bg/documents/product-information/filspari-epar-product-information_bg.pdf)

español (ES) (374.48 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/es/documents/product-information/filspari-epar-product-information_es.pdf)

čeština (CS) (397.62 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/cs/documents/product-information/filspari-epar-product-information_cs.pdf)

dansk (DA) (299.33 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/da/documents/product-information/filspari-epar-product-information_da.pdf)

Deutsch (DE) (362.75 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/de/documents/product-information/filspari-epar-product-information_de.pdf)

eesti keel (ET) (349.97 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/et/documents/product-information/filspari-epar-product-information_et.pdf)

ελληνικά (EL) (483.89 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/el/documents/product-information/filspari-epar-product-information_el.pdf)

français (FR) (306.91 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/fr/documents/product-information/filspari-epar-product-information_fr.pdf)

hrvatski (HR) (412.46 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/hr/documents/product-information/filspari-epar-product-information_hr.pdf)

íslenska (IS) (297.63 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/is/documents/product-information/filspari-epar-product-information_is.pdf)

italiano (IT) (411.04 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/it/documents/product-information/filspari-epar-product-information_it.pdf)

latviešu valoda (LV) (460.75 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/lv/documents/product-information/filspari-epar-product-information_lv.pdf)

lietuvių kalba (LT) (455.84 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/lt/documents/product-information/filspari-epar-product-information_lt.pdf)

magyar (HU) (382.67 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/hu/documents/product-information/filspari-epar-product-information_hu.pdf)

Malti (MT) (472.29 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/mt/documents/product-information/filspari-epar-product-information_mt.pdf)

Nederlands (NL) (357.66 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/nl/documents/product-information/filspari-epar-product-information_nl.pdf)

norsk (NO) (320.62 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/no/documents/product-information/filspari-epar-product-information_no.pdf)

polski (PL) (472.06 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/pl/documents/product-information/filspari-epar-product-information_pl.pdf)

português (PT) (344.43 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/pt/documents/product-information/filspari-epar-product-information_pt.pdf)

română (RO) (460.29 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/ro/documents/product-information/filspari-epar-product-information_ro.pdf)

slovenčina (SK) (459.08 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/sk/documents/product-information/filspari-epar-product-information_sk.pdf)

slovenščina (SL) (386.11 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/sl/documents/product-information/filspari-epar-product-information_sl.pdf)

Suomi (FI) (343.21 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/fi/documents/product-information/filspari-epar-product-information_fi.pdf)

svenska (SV) (273.96 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

08/12/2025

[View](/sv/documents/product-information/filspari-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** EMA/VR/0000287206 and EMA/VR/0000280770 13/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Filspari : EPAR - All authorised presentations

English (EN) (25.24 KB - PDF)

**First published:** 28/05/2024

**Last updated:** 02/07/2024

[View](/en/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-574)

български (BG) (53.39 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/bg/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_bg.pdf)

español (ES) (24.6 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/es/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.09 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/cs/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.49 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/da/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (28.89 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/de/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (24.54 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/et/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (48.46 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/el/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_el.pdf)

français (FR) (24.56 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/fr/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (48.27 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/hr/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.23 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/is/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.24 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/it/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (48.95 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/lv/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (47.88 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/lt/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (44.4 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/hu/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (72.32 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/mt/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.34 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/nl/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (24.33 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/no/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_no.pdf)

polski (PL) (35.05 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/pl/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_pl.pdf)

português (PT) (24.49 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/pt/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.34 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/ro/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (46.16 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/sk/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (45.13 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/sl/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.28 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/fi/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (24.28 KB - PDF)

**First published:**

28/05/2024

**Last updated:**

02/07/2024

[View](/sv/documents/all-authorised-presentations/filspari-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Filspari Active substance sparsentan International non-proprietary name (INN) or common name sparsentan Therapeutic area (MeSH) Glomerulonephritis, IGA Anatomical therapeutic chemical (ATC) code C09XX01

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion &gt; 1.0 g/day (or urine protein-to-creatinine ratio &gt; 0.75 g/g, see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005783

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Vifor France

100-101 Terrasse Boieldieu

Opinion adopted 22/02/2024 Marketing authorisation issued 19/04/2024 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Filspari : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (161.42 KB - PDF)

**First published:** 08/12/2025

[View](/en/documents/procedural-steps-after/filspari-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Filspari : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (127.96 KB - PDF)

**First published:** 02/07/2024

**Last updated:** 08/12/2025

[View](/en/documents/procedural-steps-after/filspari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Filspari-H-C-005783-0002 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/90836/2025

English (EN) (3.96 MB - PDF)

**First published:** 30/04/2025

[View](/en/documents/variation-report/filspari-h-c-005783-0002-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Filspari - Assessment report on maintenance of orphan designation - initial authorisation

Adopted

Reference Number: EMA/OD/0000110380

English (EN) (476.04 KB - PDF)

**First published:** 28/05/2024

**Last updated:** 03/06/2024

[View](/en/documents/orphan-maintenance-report/filspari-assessment-report-maintenance-orphan-designation-initial-authorisation_en.pdf)

Filspari : EPAR - Public assessment report

Adopted

Reference Number: EMA/106429/2024

English (EN) (2.92 MB - PDF)

**First published:** 28/05/2024

[View](/en/documents/assessment-report/filspari-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Filspari

Reference Number: EMA/518075/2023

English (EN) (142.6 KB - PDF)

**First published:** 23/02/2024

**Last updated:** 05/03/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-filspari_en.pdf)

#### News on Filspari

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2024) 23/02/2024

#### More information on Filspari

- [EU/3/20/2345 - orphan designation for treatment of primary IgA nephropathy](/en/medicines/human/orphan-designations/eu-3-20-2345)

**This page was last updated on** 08/12/2025

## Share this page

[Back to top](#main-content)